Rhumatologie

Maintenance of Infliximab Treatment in Ankylosing Spondylitis : results of one-year randomized controlled trial comparing systematic versus on-demand treatment

Arthritis & Rheumatism, Vol. 58, N° 1, January 2008, pp 88-97 Breban M, Ravaud Ph, Claudepierre P, Baron G, Henry Y-D, Hudry C, Euller-Ziegler L, Pham T, Solau-Gervais E, Chary-Valckenaere I, Marcelli C, Perdriger A, Le Loët X; Wendling D, Fautrel B, Fournié B, Combe B, Gaudin Ph, Jousse S, Mariette X, Baleydier A; Trape G, and Dougados M, for the French Ankylosing Spondylitis Infliximab Network.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France
Rhumatologie

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL
Rhumatologie

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL

Treat to target in axial spondyloarthritis: From its concept to its implementation
Rhumatologie

Treat to target in axial spondyloarthritis: From its concept to its implementation